Zymeworks ZYME
$26.14 −$0.72 (-2.68%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $26.14 0.00%
Open$26.30
Prev close$26.86
Day range$26.09 – $27.57
Volume738.8K
Market cap$1.81B
P/E (TTM)49.3
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$256.46M+828.7% YoY
Operating profit$177.63M+905.1% YoY
Net profit$173.70M+986.1% YoY
Diluted EPS$2.28+976.9% YoY
Free cash flow-$24.11M+24.2% YoY
Operating cash flow-$24.04M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin16.6%
Net margin16.3%
Return on equity15.0%
Return on assets5.5%
Return on invested capital11.2%
Current ratio3.30
Liabilities / assets78.0%
Cash & investments$100.46M
Total debt$40.69M
Net cash (debt)$59.77M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $256.46M | $4.59M | $2.41M | $105.97M | $2.52M |
| Total Operating Revenue | $256.46M | $4.59M | $2.41M | $105.97M | $2.52M |
| Operating Expense | $78.83M | $46.74M | $49.56M | $198.50M | $46.64M |
| Selling and Admin Expenses | $42.70M | $19.30M | $15.10M | $61.50M | $15.40M |
| -General & Admin Expense | $42.70M | $19.30M | $15.10M | $61.50M | $15.40M |
| Research & Development | $36.13M | $27.44M | $34.46M | $137.00M | $31.24M |
| Operating Profit | $177.63M | -$42.15M | -$47.15M | -$92.54M | -$44.12M |
| Net Non-Operating Interest Income (Expense) | -$4.21M | -$3.31M | $645,000.00 | $13.35M | $2.98M |
| Non-Operating Interest Income | $2.47M | $3.29M | $2.71M | $13.35M | $2.98M |
| Non-Operating Interest Expense | $6.69M | $6.60M | $2.07M | – | – |
| Other Income (Expense) | -$138,000.00 | $196,000.00 | $120,000.00 | -$559,000.00 | -$302,000.00 |
| Other Non-Operating Income (Expenses) | -$138,000.00 | $196,000.00 | $120,000.00 | $51,000.00 | $308,000.00 |
| Pretax Profit | $173.25M | -$45.29M | -$46.35M | -$79.75M | -$41.48M |
| Tax | -$452,000.00 | -$273,000.00 | -$2.19M | $1.38M | -$270,000.00 |
| Net Profit | $173.70M | -$45.02M | -$44.16M | -$81.13M | -$41.21M |
| Profit from Continuing Operations | $173.70M | -$45.02M | -$44.16M | -$81.13M | -$41.21M |
| Net Income to Parent Company | $173.70M | -$45.02M | -$44.16M | -$81.13M | -$41.21M |
| Net Income to Common Stockholders | $173.70M | -$45.02M | -$44.16M | -$81.13M | -$41.21M |
| Basic EPS | $2.43 | -$0.62 | -$0.59 | -$1.08 | -$0.55 |
| Diluted EPS | $2.28 | -$0.62 | -$0.59 | -$1.08 | -$0.55 |
| Gain on Sale of Security | – | – | – | -$610,000.00 | -$284,000.00 |
| Special Income (Charges) | – | – | – | $0.00 | $0.00 |
| -Less:Impairment of Capital Assets | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.18B | $396.96M | $478.22M | $346.53M | $346.53M |
| Total Current Assets | $532.40M | $298.39M | $385.68M | $248.77M | $248.77M |
| Cash and Cash Equivalents & Short-Term Investments | $100.46M | $270.70M | $364.73M | $228.80M | $228.80M |
| -Cash and Cash Equivalents | $100.46M | $179.41M | $244.28M | $41.16M | $41.16M |
| -Short Term Investments | $0.00 | $91.29M | $120.45M | $187.64M | $187.64M |
| Receivables | $413.86M | $5.93M | $4.67M | $4.64M | $4.64M |
| -Accounts Receivable | $413.86M | $5.93M | $4.67M | $4.64M | $4.64M |
| Other Current Assets | $18.07M | $21.76M | $16.28M | $15.33M | $15.33M |
| Total Non-Current Assets | $644.02M | $98.58M | $92.54M | $97.76M | $97.76M |
| Net PPE | $63.50M | $27.15M | $28.87M | $31.23M | $31.23M |
| -Gross PPE | $63.50M | $27.15M | $28.87M | $52.10M | $52.10M |
| Investments and Advances | $0.00 | $51.78M | $39.12M | $41.79M | $41.79M |
| Goodwill and Other Intangible Assets | $547.43M | $13.01M | $13.19M | $13.37M | $13.37M |
| -Goodwill | $116.40M | $12.02M | $12.02M | $12.02M | $12.02M |
| -Other Intangible Assets | $431.03M | $998,000.00 | $1.17M | $1.35M | $1.35M |
| Non-Current Deferred Assets | $5.84M | $4.35M | $4.71M | $4.71M | $4.71M |
| Other Non-Current Assets | $27.24M | $2.28M | $6.65M | $6.67M | $6.67M |
| Total Liabilities | $918.16M | $316.60M | $314.63M | $78.03M | $78.03M |
| Total Current Liabilities | $161.46M | $47.24M | $35.65M | $42.32M | $42.32M |
| Payables | $132.37M | $27.50M | $30.29M | $4.91M | $4.91M |
| -Accounts Payable | $131.86M | $27.46M | $30.23M | $4.40M | $4.40M |
| -Total Tax Payable | $505,000.00 | $45,000.00 | $66,000.00 | $508,000.00 | $508,000.00 |
| Short-Term Debt and Capital Lease Obligation | $12.44M | $3.30M | $3.28M | $3.47M | $3.47M |
| -Current Capital Lease Obligation | $12.44M | $3.30M | $3.28M | $3.47M | $3.47M |
| Current Deferred Liabilities | $16.66M | $16.44M | $2.08M | $2.42M | $2.42M |
| Total Non-Current Liabilities | $756.70M | $269.35M | $278.98M | $35.71M | $35.71M |
| Long Term Accounts Payable and Other Payables | $91.56M | – | – | – | – |
| Long Term Debt and Capital Lease Obligation | $40.69M | $12.70M | $13.76M | $14.80M | $14.80M |
| -Long Term Capital Lease Obligation | $40.69M | $12.70M | $13.76M | $14.80M | $14.80M |
| Non-Current Deferred Liabilities | $26.77M | $3.74M | $18.43M | $20.63M | $20.63M |
| Other Non-Current Liabilities | $597.67M | $252.91M | $246.78M | $278,000.00 | $278,000.00 |
| Total Equity | $258.25M | $80.37M | $163.59M | $268.50M | $268.50M |
| Stockholders' Equity | $258.25M | $80.37M | $163.59M | $268.50M | $268.50M |
| Capital Stock | $1.15B | $1.14B | $1.14B | $1.11B | $1.11B |
| -Common Stock | $1.15B | $1.14B | $1.14B | $1.11B | $1.11B |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $127.22M | $116.45M | $107.53M | $114.63M | $114.63M |
| Retained Earnings | -$1.01B | -$1.17B | -$1.07B | -$953.16M | -$953.16M |
| Gains/Losses Not Affecting Retained Earnings | -$6.66M | -$6.69M | -$6.57M | -$6.08M | -$6.08M |
| -Available for Sale Securities | – | $51.78M | $39.12M | – | – |
| -Accumulated Depreciation | – | – | – | -$20.88M | -$20.88M |
| Current Accrued Expenses | – | – | – | $21.85M | $21.85M |
| Other Current Liabilities | – | – | – | $844,000.00 | $844,000.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$24.04M | -$31.95M | -$45.72M | -$33.01M | -$10.26M |
| Net cash flow from continuing operations | -$24.04M | -$31.95M | -$45.72M | -$33.01M | -$10.26M |
| Net Income from Continuing Operations | $173.70M | -$45.02M | -$44.16M | -$81.13M | -$41.21M |
| Gain/Loss from Continuing Operations | $78,000.00 | -$301,000.00 | -$331,000.00 | $532,000.00 | $305,000.00 |
| Depreciation & Depletion & Amortization | $2.54M | $1.95M | $2.85M | $11.11M | $2.01M |
| Deferred Tax | -$1.57M | $265,000.00 | -$2.20M | $945,000.00 | $1.41M |
| Other Non-Cash Items | $6.16M | $6.13M | $2.07M | – | – |
| Change in Working Capital | -$228.02M | -$6.31M | -$10.87M | $7.50M | $18.38M |
| -Change in Receivables | -$290.91M | -$1.26M | -$36,000.00 | $51.20M | $24.71M |
| -Change in Prepaid Assets | $6.20M | -$383,000.00 | -$1.73M | $6.51M | -$5.12M |
| -Change in Payables and Accrued Expense | $57.28M | -$3.64M | -$7.77M | -$23.69M | $402,000.00 |
| -Change in Other Current Liabilities | -$821,000.00 | -$783,000.00 | -$1.01M | -$3.34M | -$838,000.00 |
| -Change In Other Working Capital | $223,000.00 | -$248,000.00 | -$340,000.00 | -$23.17M | -$779,000.00 |
| Net cash flow from investing | -$389.77M | $17.07M | $69.96M | $26.66M | $5.37M |
| Net Cash Flow from Continuing Investing Activities | -$389.77M | $17.07M | $69.96M | $26.66M | $5.37M |
| Net PPE Purchase and Sale | -$73,000.00 | $0.00 | -$216,000.00 | -$1.52M | -$581,000.00 |
| Net Intangibles Purchase and Sale | $0.00 | $0.00 | $0.00 | -$831,000.00 | -$139,000.00 |
| Net Investment Purchase and Sale | $142.32M | $17.07M | $70.18M | $29.02M | $6.09M |
| Financing Cash Flow | $334.85M | -$50.02M | $178.79M | -$18.56M | -$18.74M |
| Net Cash Flow from Continuing Financing Activities | $334.85M | -$50.02M | $178.79M | -$18.56M | -$18.74M |
| Net Common Stock Issuance | -$261.99M | -$51.95M | $173.85M | -$36.71M | -$25.48M |
| Proceeds from Stock Option Exercised | $2.88M | $2.89M | $9.32M | $18.33M | $6.83M |
| Net Other Financing Charges | $593.96M | -$958,000.00 | -$4.39M | -$181,000.00 | -$88,000.00 |
| Ending Cash Balance | $100.46M | $179.41M | $244.28M | $41.16M | $41.16M |
| Net Change in Cash | -$78.96M | -$64.89M | $203.03M | -$24.90M | -$23.63M |
| Beginning Cash Balance | $179.41M | $244.28M | $41.16M | $66.10M | $64.83M |
| Effect of Exchange Rate Changes | $11,000.00 | $24,000.00 | $98,000.00 | -$45,000.00 | -$44,000.00 |
| Free Cash Flow | -$24.11M | -$31.95M | -$45.93M | -$35.36M | -$10.98M |
No comments yet — be the first to weigh in on ZYME.
Sign in to join the discussion.